OGEN News and Press, Oragenics Inc. From 02/12/24

Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company’s Chief...

2024-02-07 12:58:21 ET More on Mid-day movers & stocks. Zenvia Inc. (ZENV) Q3 2023 Earnings Call Transcript Zenvia reports Q3 results Byron Allen looking at Scripps stations, seeks funding - report Financial information for Oragenics Seeking Alpha...

Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that its engagement agreement with its investment bank has expired and that it does not intend to extend the engageme...

Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced it is preparing for a Phase II clinical trial using its novel drug - device combination for the treatment of mild Tra...

2024-01-23 17:46:25 ET Oragenics ( NYSE: OGEN ) said Tuesday it has terminated its previously announced at-the-market equity offering program. The termination is expected to take effect on January 30, 2024. Press Release . Shares +6.6% at $5.49 after hours. ...

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has terminated its previously announced “at-the-market” (“ATM”) equity offering program. The Company has initiated the 5-day termination process of t...

2024-01-04 12:34:16 ET More on Mid-day movers & Stocks. Relmada Therapeutics, Inc. (RLMD) Q3 2023 Earnings Call Transcript Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024 Avenue Therapeutics GAAP EPS of $0.06 beats by $0.32 ...

Adds Clinical-Stage Product Pipeline, Expands Intranasal Drug Delivery Technologies, Names Michael Redmond as President of Oragenics Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces it has completed its previously announc...

Oragenics, Inc. (NYSE American: OGEN): Fellow Shareholders, As our annual meeting date approaches and in response to valuable feedback from our shareholders, I believe it important to highlight and summarize some of the information in our proxy statement regarding the proposed increase in...

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023. “We are delighted to welcome Bruce Cassidy and John Gandolfo to the Oragen...